A dominant negative mutation of the alpha retinoic acid receptor gene in a retinoic acid-nonresponsive embryonal carcinoma cell.
AUTOR(ES)
Pratt, M A
RESUMO
Pluripotential embryonal carcinoma cells such as those of the P19 line differentiate when exposed to retinoic acid (RA). The RAC65 cell line is a mutant clone of P19 cells selected to be RA nonresponsive. RAC65 cells carry a rearrangement affecting one of the genes encoding a nuclear retinoic acid receptor (RAR alpha). The mutant gene encodes a protein, RAR alpha', that has lost its 70 C-terminal amino acids, thus truncating the RA-binding domain. The RAR alpha' was found to be a dominant repressor of transcription from an RA-responsive target gene; however, expression of RAR alpha' was insufficient to confer RA nonresponsiveness, suggesting that RAC65 cells carry an additional mutation(s) affecting RA-induced genes.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=362921Documentos Relacionados
- Dominant negative retinoid X receptor beta inhibits retinoic acid-responsive gene regulation in embryonal carcinoma cells.
- Functional inhibition of retinoic acid response by dominant negative retinoic acid receptor mutants.
- A dominant negative retinoic acid receptor blocks neutrophil differentiation at the promyelocyte stage.
- Retinoic acid-induced neural differentiation of embryonal carcinoma cells.
- Thrombomodulin gene regulation by cAMP and retinoic acid in F9 embryonal carcinoma cells.
